Keros Triggers $20M Milestone from Takeda as Elritercept Phase 3 Begins; Plans 25% Payout to Shareholders
KROS is trading near its 52-week low of $9.69 (7.0% above the low).
Summary
Keros Therapeutics earned a $20 million milestone payment from Takeda after dosing the first patient in the Phase 3 ELRiSE MDS trial of elritercept. The company plans to distribute 25% of the net proceeds to shareholders.
Key Events · Product Development and Regulatory · KROS
-
Phase 3 Trial Start Triggers $20M Milestone
Dosing of the first patient in the ELRiSE MDS Phase 3 trial of elritercept triggered a $20 million development milestone payment from partner Takeda under the January 2025 license agreement.
-
25% of Net Proceeds to Be Distributed to Stockholders
Keros expects to distribute 25% of the net cash proceeds from the milestone payment to stockholders following receipt, an unusual direct return of capital alongside clinical progress.
-
Non-Dilutive Cash Strengthens Balance Sheet
The $20 million milestone adds to the $281 million cash position reported as of Q1 2026, providing additional runway without dilution.
-
Elritercept Program Advances Toward Registration
The Phase 3 ELRiSE MDS trial compares elritercept to epoetin alfa in anemia due to low-risk MDS, building on positive Phase 2 signals and moving the program closer to potential approval.
Analysis · KROS · Life Sciences
Dosing the first patient in the Phase 3 ELRiSE MDS trial unlocks a $20 million development milestone from partner Takeda under the 2025 license agreement. Keros intends to distribute 25% of the net proceeds directly to stockholders — an unusual move that returns capital while the pivotal trial advances. The milestone adds non-dilutive cash to a balance sheet that held $281 million as of Q1 2026, and the Phase 3 start de-risks the elritercept program, which already generated a $200 million upfront payment.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KROS was trading at $10.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.3M. The 52-week trading range was $9.69 to $22.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.